Independent investing research and personal finance for IrelandUnderstand. Decide. Compound.

Wealth5 min read

Magnera Generated $115 Million of Free Cash Flow. Is That Enough for $1.85 Billion of Debt?

Magnera produced record cash flow and paid down debt even as organic volume fell. We examine whether price-cost gains and restructuring can make deleveraging durable.

Rolls of brightly coloured non-woven fabric; a representative materials photograph captured in December 2017, not identified as Magnera product.Wealth / The Compound journal

Photo: Anh Nhi Đỗ Lê / Wikimedia Commons, CC0 1.0. Representative non-woven materials photograph captured 18 December 2017; cropped and resized for publication. · Illustrative image.

Magnera’s first full fiscal year after the Glatfelter–Berry materials combination produced a useful contradiction. The company generated record cash flow and repaid debt, yet organic volume fell and year-end debt remained more than four times adjusted EBITDA.

For the year ended 26 September 2026, the maker of nonwoven and specialty materials reported $3.30 billion of net sales, $378 million of adjusted EBITDA and $115 million of free cash flow. It repaid $122 million of debt, but finished with $1.85 billion of current and long-term debt and $294 million of cash.

That leaves a more important investment question than whether fourth-quarter profit beat a forecast: can cost savings and price discipline turn weak volume into enough recurring cash to reduce leverage?

Compound does not currently maintain a dedicated Magnera stock profile, so this analysis does not invent one or repeat a routine earnings table.

Price covered softer demand

Fourth-quarter net sales rose 1% to $851 million, while adjusted EBITDA increased 8% to $97 million. The sales increase did not come from more product moving through Magnera’s plants. Organic volume declined 4%, primarily because of softer healthcare demand in the Americas and continued market weakness in Europe.

Instead, selling-price increases added $43 million, mainly passing through higher raw-material costs. Management attributed the adjusted EBITDA improvement primarily to a favourable $9 million price-cost spread.

Passing through input inflation is a real commercial strength. It suggests customer contracts and product positions can protect gross economics when raw-material costs change. But price-cost spread is not the same as volume growth. A manufacturer has fixed assets, labour and overheads to absorb; prolonged under-utilisation can eventually erode the savings that support margin.

The full-year comparison contains the same warning. Reported net sales increased 3%, but sales on a comparable basis were down 4%. Adjusted EBITDA grew 7% as reported and 4% on a comparable basis. Currency, acquisition effects and pricing made the headline stronger than the underlying demand picture.

Cash improved faster than accounting profit

Magnera recorded a $37 million operating loss for the year. That included $106 million of goodwill and other impairment charges, which reduced accounting profit without consuming current-period cash. Adjusted EBITDA removes that and other items, so neither measure should be used alone.

The cash-flow statement provides a clearer bridge. Operating activities generated $178 million, while net additions to property, plant and equipment were $63 million. Magnera defines the $115 million difference as free cash flow. The arithmetic is straightforward, but free cash flow remains a non-GAAP measure and does not eliminate refinancing needs.

The company used $122 million for long-term debt repayments. Free cash flow therefore covered about 94% of those repayments. That is encouraging: deleveraging was supported mostly by operations rather than by a new equity issue or a major asset sale.

The scale still matters. Subtracting $294 million of cash from $1.848 billion of debt gives approximately $1.55 billion of net debt, a simple Compound calculation. Fiscal 2026 free cash flow equalled only about 7.4% of that amount. One year at this pace would improve leverage, not transform it.

The merger must deliver more than adjustments

Magnera was created in November 2024 when the former Glatfelter combined with Berry Global’s health, hygiene and specialties business. The June 2026 Form 10-Q says Project CORE plant rationalisation and cost initiatives were intended to counter general economic softness. It also identifies integration and synergy realisation as central to the operating structure.

That context makes adjusted EBITDA useful but also raises the evidential bar. Savings are valuable only if they survive after restructuring charges, impairments and merger-related costs subside. A business cannot rely indefinitely on describing costs as outside core performance while using adjusted profit to judge leverage.

Debt also carries rate risk. At the June quarter-end, Magnera’s $706 million term loan bore SOFR plus 4.25 percentage points. The filing estimated that a 0.25-point change in floating rates would move annual interest expense by about $2 million. Lower principal and refinancing on better terms would therefore help cash conversion directly.

Guidance implies progress, not a clean escape

Management guides to $390 million–$410 million of adjusted EBITDA, $195 million–$215 million of operating cash flow and $110 million–$130 million of free cash flow for fiscal 2027. The midpoint implies adjusted EBITDA growth of roughly 5.8% and free cash flow of $120 million, only modestly above fiscal 2026.

Those are management targets, not Compound forecasts. The company also says it cannot provide a GAAP reconciliation for forward adjusted EBITDA and free cash flow without unreasonable effort because several items are uncertain and potentially material.

The constructive case would be strengthened by organic volumes stabilising, price-cost gains persisting without customer losses, and free cash flow moving above guidance while debt falls. Fewer restructuring and impairment adjustments would make the profit bridge more credible.

The case would weaken if falling volumes absorb the benefits of Project CORE, if free cash flow stalls near $100 million while refinancing costs remain high, or if acquisitions take priority over deleveraging. A rise in debt despite positive free cash flow would be an especially important warning.

Magnera has proved that it can extract cash from a difficult demand year. It has not yet proved that the resulting cash is large enough, or durable enough, to make its leverage comfortable. The next phase needs both operational demand and debt reduction—not merely another adjusted-earnings improvement. This analysis makes no price target.

Explore Compound’s earnings hub and our guide to investment diversification.

Reported figures are in US dollars. Adjusted EBITDA, comparable-basis sales and free cash flow are company-defined non-GAAP measures; guidance is management’s and may not be achieved. Facts come from Magnera’s SEC-furnished results release, Form 8-K and June-quarter Form 10-Q. Net debt, coverage and growth calculations are Compound’s. General information, not personal investment advice.

Cover: Anh Nhi Đỗ Lê, Wikimedia Commons, dedicated to the public domain under CC0 1.0. Captured 18 December 2017. Representative non-woven materials image; not identified as Magnera product. Cropped and resized for publication.

YOUR PRIVACY

Help us understand what gets read.

With your permission, anonymous Google Analytics measurements tell us which articles are useful. We do not send calculator entries or form values. You can decline and still read everything.